Published online before print April 24, 2006, doi: 10.1161/CIRCULATIONAHA.105.598086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:2113-2119.)
© 2006 American Heart Association, Inc.
Valvular Heart Disease |
Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis
From the University of Washington (R. Katz, R. Kronmal, J.L.P., K.D.O.), Seattle, Wash; University of California (N.D.W.), Irvine, Calif; Harbor-UCLA Research and Education Institute (J.T., D.M.S., M.J.B.), Torrance, Calif; and Wake Forest University Health Sciences (A.G.B.), Winston-Salem, NC.
Correspondence to Kevin D. O’Brien, MD, Division of Cardiology, Box 354622, University of Washington, 1959 NE Pacific St, Seattle, WA
Received November 8, 2005; revision received February 9, 2006; accepted February 24, 2006.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Calcific aortic valve disease is common in the elderly, is correlated with common cardiovascular risk factors, and is associated with increased cardiovascular event risk; however, whether metabolic syndrome is associated with an increased prevalence of aortic valve calcium (AVC) is not known.
Methods and Results— The prevalence of AVC, as assessed by computed tomography, was compared in 6780 Multi-Ethnic Study of Atherosclerosis (MESA) participants with metabolic syndrome (n=1550; National Cholesterol Education Program’s Adult Treatment Panel III [ATP III] criteria), diabetes mellitus (n=1016), or neither condition (n=4024). The prevalence of AVC for those with neither condition, metabolic syndrome, or diabetes mellitus was, respectively, 8%, 12%, and 17% in women (P<0.001) and 14%, 22%, and 24% in men (P<0.001). Compared with those with neither condition, the adjusted relative risks for the presence of AVC were 1.45 (95% CI 1.11 to 1.90) for metabolic syndrome and 2.12 (95% CI 1.54 to 2.92) for diabetes mellitus in women and 1.70 (95% CI 1.32 to 2.19) for metabolic syndrome and 1.73 (95% CI 1.33 to 2.25) for diabetes mellitus in men. There was a graded, linear relationship between AVC prevalence and the number of metabolic syndrome components in both women and men (both P<0.001). Similar results were obtained when the International Diabetes Federation metabolic syndrome definition was used.
Conclusions— In the MESA cohort, the metabolic syndrome and diabetes mellitus are associated with increased risk of AVC, and AVC prevalence is increased with increasing number of metabolic syndrome components.
Key Words: calcium • diabetes mellitus • tomography • valves • metabolic syndrome
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Aortic valve calcification (AVC) is common in the elderly, and its presence is associated with an increased risk of cardiovascular events.1 AVC is a characteristic of aortic sclerosis, in which the aortic valve is calcified but does not obstruct left ventricular outflow, and aortic stenosis, in which obstruction to left ventricular outflow is present.2 Aortic sclerosis has a prevalence of 25% in patients above the age of 65 years3 and has been associated with a 50% increase in risk for cardiovascular mortality.1 In one retrospective cohort study, subjects with aortic sclerosis were
16 times more likely to develop aortic stenosis than were those with normal valves.4 Aortic stenosis carries an 80% 5-year risk of heart failure, valve replacement, or death.5 Histopathological studies have demonstrated that aortic valvular lesions have many features characteristic of atherosclerotic lesions, including chronic inflammation,6,7 lipoprotein deposition,8,9 and the presence of ACE.10 In addition, risk factors for atherosclerosis, including age, hypercholesterolemia, smoking, and male gender, also are associated with an increased AVC prevalence.3 The identification of factors associated with AVC may be important, because there currently are no medical therapies that have been shown conclusively either to slow AVC progression or to decrease clinical events associated with AVC.
Clinical Perspective p 2119
Recently, multiple investigators have identified the insulin resistance/metabolic syndrome as a major cardiovascular risk factor.(reviewed in Grundy et al11,12) The metabolic syndrome (MetS) is identified clinically by the presence of a constellation of features, including central adiposity, dyslipidemia, hypertension, and impaired fasting glucose.11–13 The prevalence of MetS is high14 and is increasing, owing in part to the epidemic of obesity.15 Previous studies have shown that MetS and diabetes mellitus are associated with increased coronary artery calcium scores, as assessed by electron-beam computed tomography.16,17 Diabetes mellitus has been shown in echocardiographic studies to be associated with increased prevalences of aortic valve calcium18 and aortic stenosis,19 as well as with an increased rate of aortic stenosis progression.20 However, no previous studies have investigated whether MetS is associated with increased AVC prevalence, as assessed either by echocardiography or by electron-beam computed tomography.
We analyzed data from the Multi-Ethnic Study of Atherosclerosis (MESA) to determine whether, at baseline, features of MetS (waist circumference, blood pressure, low HDL cholesterol, high triglycerides, and impaired fasting glucose) were associated, either individually or collectively, with increased AVC scores. We also determined the prevalence and quantity of AVC among persons with MetS, diabetes mellitus, or neither condition.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
The MESA cohort consists of 6814 men and women aged 45 to 84 years who were recruited from 6 US communities (Baltimore, Md; Chicago, Ill; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan, NY; and St. Paul, Minn) and who were free of clinically evident cardiovascular disease at the time of enrollment. The main objective of MESA is to determine the characteristics of subclinical cardiovascular disease and its progression. In MESA, participants were free of clinical CVD at baseline. Participants were excluded if they had a history of any of the following procedures: coronary bypass surgery, balloon angioplasty, heart valve replacement, pacemaker or defibrillator implantation, or any other cardiac surgery. Of the 6780 participants, 168 (2.5%) had self-reported rheumatic fever; the exclusion of these people from the analysis did not change the results. The study was designed to include whites, blacks, Hispanics, and Chinese. Sampling and recruitment procedures have been described in detail previously.21 Participants were enrolled between August 1, 2000, and July 30, 2002. The institutional review boards at all participating centers approved the study, and all participants gave informed consent.
Questionnaires were used to obtain information about socioeconomic status, medical history, medication, and tobacco use. Smoking was defined as current, former, or never. Waist circumference at the umbilicus was measured to the nearest 0.1 cm with a steel measuring tape (standard 4-oz tension). Resting blood pressure was measured 3 times with participants in the seated position with a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon/GE Healthcare; Giles, Bucks, United Kingdom). The average of the last 2 measurements was used in analysis. Total and HDL cholesterol, triglycerides, and glucose levels were measured from blood samples obtained after a 12-hour fast. LDL cholesterol was calculated with the Friedewald equation.22 Diabetes was defined as fasting glucose 
126 mg/dL or use of hypoglycemic medication. Impaired fasting glucose was defined as fasting glucose 110 to 125 mg/dL.
MetS Definitions
MetS was defined with the Third Adult Treatment Panel of the National Cholesterol Education Program (ATP III)23 modified criteria as the presence of 3 or more of the following: large waist circumference (women >88 cm and men >102 cm); elevated triglycerides (150 mg/dL); low HDL cholesterol (men <40 mg/dL and women <50 mg/dL); impaired fasting glucose (110 to 125 mg/dL); and elevated blood pressure (130/85 mm Hg or self-reported use of medications for hypertension). The American Diabetes Association recently recommended that the range for impaired fasting glucose be changed from 110 to 125 mg/dL to 100 to 125 mg/dL24; the effect of this modification on the population prevalence of MetS has not been fully explained. Therefore, a revised definition of MetS that applied the lower threshold for impaired fasting glucose (100 to 125 mg/d) was created to assess the effect of this change on the prevalence of MetS and its association with AVC. As a secondary analysis, we also examined the International Diabetes Federation (IDF) criteria for MetS,13 which recommend large waist circumference (for whites, blacks, and Hispanics: 80 cm if female or 94 cm if male; for Chinese, 80 cm if female or 90 cm if male) and 2 or more of the following: elevated triglycerides (150 mg/dL); low HDL cholesterol (men <40 mg/dL and women <50 mg/dL); impaired fasting glucose (100 to 125 mg/dL); and elevated blood pressure ( 130/85 mm Hg or self-reported use of medications for hypertension).
Computed Tomography Techniques
All participants underwent 2 computed tomography (CT) scans at the same time for evaluation of coronary artery calcium. CT studies were performed with either an Imatron C-150XL computed tomographic scanner (GE-Imatron, South San Francisco, Calif) in 3 sites or multidetector CT scanners (4-slice) in 3 sites. The exact scanning methodology employed in the MESA study has been reported elsewhere.25
All studies were analyzed at the MESA CT reading center at Harbor-UCLA Research and Education Institute. The calcium score of each lesion was calculated by multiplying the lesion area by a density factor derived from the maximal Hounsfield units within this area, as described by Agatston et al.26 The density factor was assigned in the following manner: 1 for lesions for which the maximal density was 130 to 199 HU, 2 for lesions 200 to 299 HU, 3 for lesions 300 to 399 HU, and 4 for lesions >400 HU. A total calcium score (for both Agatston and volume) was determined by summing individual lesion scores at each anatomic site. Volume of calcium was also measured (in mm3) as the volumetric score.27
AVC was measured and quantified with the same lesion definition as for coronary calcification. Any calcified focus seen that extended to the aortic root was deemed aortic valve calcium, by methodology described previously.28 Calcification that involved either the aortic or mitral annuli was not included. AVC score (Agatston and volume) was assessed in every patient. The absence of AVC was deemed a score of 0.
Data Analyses
The study population for the present analysis includes all MESA participants who had no missing data on any component of MetS. After the application of these criteria, 6780 individuals remained for analysis.
All analyses were stratified by gender. Comparisons between MetS, diabetes mellitus, and neither condition (and across number of MetS risk factors) with demographic measures and cardiovascular risk factors are expressed with means and proportions. We used the 
2 test for proportions and ANOVA for comparison of levels of continuous risk factors.
Because the prevalence of calcification was >10% in the cohort, ORs overestimate the relative risk (RR). Therefore, RR estimates are presented from the regression model y=exp(XTß). The exponentiated parameters ß are interpreted as RRs. We assumed gaussian error and used robust standard error estimates. Using this method, we examined the prevalence of AVC >0 (ie, the percent with scores >0) among the 3 disease groups (MetS, diabetes mellitus, and neither condition) by gender, adjusted for age and ethnicity and additionally for other non-MetS risk factors (LDL cholesterol, lipid-lowering medications, and smoking). Among those with detectable calcium, the natural logarithm of the AVC score was used as a continuous variable in a linear regression. For all nondiabetic subjects, we further examined the number of MetS risk factors (from none to all 5) and their association with prevalence of AVC and examined the RR of AVC >0 by number of MetS risk factors using those with 0 MetS risk factors as the reference group. For the RR regression, participants who had 4 and 5 risk factors were grouped together owing to the relatively small numbers. Two-way interactions between MetS (and diabetes mellitus) and age and ethnicity with the outcomes of interest were examined.
Statistical analyses were performed with SPSS 12.0.2 software for Windows (SPSS Inc, Chicago, Ill) and Stata 8.0 for Windows (Stata Co, College Station, Tex). A probability value <0.05 was considered statistically significant. Confidence intervals are expressed as 95% CIs.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Participant Characteristics
The mean age of the cohort was 62 years (range 45 to 85 years); 53% were female; 12% were Chinese-American, 28% were black, and 22% were Hispanic. Of the 6780 participants, 1550 (23%) met the ATP III definition for MetS and an additional 1026 (15%) met the definition for diabetes mellitus. There were significant differences in all coronary risk factors between those without either MetS or diabetes, those with MetS, and those with diabetes (Table 1). The prevalence of MetS in participants without diabetes was 30% in women and 21% in men, with substantial differences by gender and ethnic subgroups (from a low of 13% in Chinese-American men to a high of 31% in Hispanic women). Elevated blood pressure was the most common component for men, ranging from 81% in subjects with MetS to 80% in subjects with diabetes. Large waist circumference was much more prevalent in women (94% for those with MetS and 87% for those with diabetes) than in men (75% for MetS and 51% for diabetes). With the IDF definition of MetS, 2239 participants (33%) had MetS, with MetS prevalences of 35% in women and 31% in men. With the IDF definition, the prevalence of MetS also differed by ethnicity, ranging from 11% in Chinese women to 32% in both black women and white women and from 8% in Chinese men to 38% in white men.
|
Relationships of MetS and Diabetes Mellitus to AVC Prevalence
The prevalence of AVC in women with MetS was significantly lower (12%) than in those with diabetes (17%) and significantly higher than in those with neither condition (8%; both P<0.001). In men, the prevalence of AVC in those with MetS was 22% compared with 24% in those with diabetes and 14% in those with neither condition (P<0.001; Figure 1A). Similar results were observed with the IDF criteria for MetS (Figure 1B).
|
Among women with detectable calcium who had neither MetS nor diabetes, the mean of ln(AVC) was 3.76 (SD=1.28); the mean for those with MetS was 3.80 (SD=1.68) compared with the mean among diabetic subjects of 4.00 (SD=1.15). The difference between these means was not significant (P=0.407). For men, these figures were 4.16 (SD=1.63), 4.21 (SD=1.53), and 4.28 (SD=1.55), respectively (P=0.779). We tested for interactions between MetS and either age or ethnicity in the prediction of the presence of AVC. There were no significant interactions with age or ethnicity (all P>0.10).
Relationship of AVC Prevalence to Number of MetS Components
There was a graded, linear association between the prevalence of AVC and the number of metabolic risk factors (excluding persons with diabetes) for both genders (Figure 2A). For women, AVC prevalence ranged from 3% in those without any metabolic risk factors to 7%, 11%, 12%, 15%, and 17% in those with 1, 2, 3, 4, and 5 metabolic risk factors, respectively (P<0.001 for trend). For men, the prevalence of AVC was higher and ranged from 9% in those without any metabolic risk factors to 15%, 17%, 22%, 23%, and 30% in those with 1, 2, 3, 4, and 5 metabolic risk factors, respectively (P<0.001 for trend). Similar results were obtained when the IDF definition of MetS was used (Figure 2B)
|
Regression Analyses of MetS, Diabetes Mellitus, and AVC Risk
From RR regression analyses, the RR of AVC (compared with those with neither MetS nor diabetes mellitus), adjusted for age and ethnicity, was significantly higher in both women and men among those with MetS (women: RR 1.49, 95% CI 1.14 to 1.96; men: RR 1.70, 95% CI 1.32 to 2.18) and diabetes (women: RR 2.20, 95% CI 1.61 to 3.01; men: RR 1.72, 95% CI 1.33 to 2.23). Additional adjustment for LDL cholesterol, lipid-lowering medication use, and cigarette smoking showed these relations to persist (women with MetS: RR 1.45, 95% CI 1.11 to 1.90; men with MetS: RR 1.70, 95% CI 1.32 to 2.19; women with diabetes: RR 2.12, 95% CI 1.54 to 2.92; and men with diabetes: RR 1.73, 95% CI 1.33 to 2.25; Table 2). For the IDF definition of MetS, the RR of AVC adjusted for age, gender, LDL cholesterol, lipid-lowering medication use, and cigarette smoking was still significantly higher in both men and women than in those with neither condition (women: RR 1.43, 95% CI 1.10 to 1.86; men: RR 1.40, 95% CI 1.12 to 1.76). The IDF definition of MetS also had no effect on the severity of AVC (women: RR 1.89, 95% CI 0.99 to 3.62; men: RR 1.19, 95% CI 0.77 to 1.85).
|
Application of the new, lower limit of fasting glucose (100 mg/dL) resulted in a nearly 3-fold increase in the prevalence of impaired fasting glucose (from 12% to 35%) and an additional 7% for the total population classified as having MetS. Furthermore, fully adjusted RRs estimated from the revised criteria of MetS that used the 100 to 125 mg/dL range for fasting glucose were very similar to those estimated when we used the original impaired fasting glucose criteria (when the adjusted model [model 2] from Table 2 was used, AVC >0 yielded a 1.43 RR in women [95% CI 1.10 to 1.85] and 1.50 RR in men [95% CI 1.19 to 1.89]).
In age- and ethnicity-adjusted models performed separately for each component of the MetS (Table 3), elevated blood pressure, high triglycerides, and abdominal obesity were significantly associated with AVC, with approximately 45%, 45% to 60%, and 35% to 60% increases, respectively, in AVC prevalence. Remaining components were less strongly associated with AVC. When all 5 of the components of MetS were included in a single model, the RR for elevated blood pressure was attenuated slightly but still exhibited the strongest association with AVC relative to the other components (results not shown).
|
Regression Analyses of the Relationship of Number of MetS Components to the Presence of AVC
To examine the association between the number of components and presence of AVC, sex-specific models were fit with categories that represented the presence of 1, 2, 3, and 4 components, with 0 components as the referent (Table 4). Women and men with 4 to 5 components were 3.32 (95% CI 1.77 to 6.21) and 2.26 (95% CI 1.72 to 3.86) times more likely to have AVC than participants with 0 components. Furthermore, the presence of any 2 components was positively associated with presence of AVC (women: 2.44, 95% CI 1.32 to 4.50; men: 1.46, 95% CI 1.01 to 2.11). When the new lower limit of fasting glucose (100 mg/dL) was used, the magnitude of association between each number of remaining components and prevalence of AVC remained nearly the same (for 4 to 5 components, the RR in women was 3.32 [95% CI 1.71 to 6.45], and in men, the RR was 2.32 [95% CI 1.54, 3.52]). When we applied the IDF definition, sex-specific models were fit that represented the abdominal obesity criteria plus the presence of 0, 1, 2, or 3 components, with no abdominal obesity present as the referent (Table 4). Women and men with abdominal obesity plus 3 to 4 components were 1.72 (95% CI 1.01 to 2.90) and 1.92 (95% CI 1.39 to 2.66) times more likely to have AVC than participants with no abdominal obesity; however, the presence of fewer components plus abdominal obesity had no significant association with AVC in either men or women.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our report of a large, population-based multiethnic cohort shows an increased and graded likelihood of AVC with the presence of MetS and diabetes mellitus, as well as with the number of MetS risk factors. Increased calcification in coronary arteries and the aorta have been associated with MetS and diabetes,16,17 which underscores the potential similarities in the pathogeneses of atherosclerosis and AVC. The present results of an increased likelihood of AVC in those with MetS and diabetes hold true both for men and for women and after adjustment for other non-MetS risk factors. The present investigation is the first to demonstrate, in a large, population-based, multiethnic cohort, that MetS and diabetes are independently associated with AVC. Moreover, there was a graded, linear relationship between the number of MetS components and RR for the presence of AVC, which further strengthens the association of MetS with AVC.
The mechanisms by which MetS might mediate increased valvular calcification are not known. However, MetS is associated with increased oxidant and inflammatory stress, and both oxidized cholesterol and inflammatory cytokines, each of which is present in human aortic valve lesions,9,29 have been shown to increase calcific nodule formation by valvular fibroblasts in vitro.30
This study has several limitations: (1) It is cross-sectional, which limits conclusions about causality; (2) the study may be subject to survival bias in that individuals with cardiovascular disease did not participate in MESA; (3) because MESA is limited to adults free of clinical cardiovascular disease at baseline, many individuals with MetS and preexisting cardiovascular disease who were at high risk for AVC may have been excluded, thereby diminishing the strengths of association; and (4) dichotomous representations of truly continuous measures, such as those that constitute the MetS criteria, decrease available information and can result in misclassification of exposure. This is especially true for measures with known biological variability and thus may account for the relatively weak association detected between low HDL and prevalent AVC observed in the present study. However, the purpose of the study was to investigate the associations between AVC and MetS and its individual components as defined by ATP III, in which specific threshold values have been recommended. It is reassuring that the results were similar when the recently released IDF metabolic syndrome definition13 was used. In addition, one recent recommendation has been to lower the impaired fasting glucose cutpoint to 100 mg/dL, and it is noteworthy that the relationship between MetS and AVC remains robust even when MetS is defined with this lower glucose cutpoint.
Moreover, we recognize that persons with MetS and diabetes mellitus represent a spectrum of risk; it is possible that AVC prevalence could be highest in those with diabetes who also have multiple MetS risk factors, and lower in those with diabetes without other MetS risk factors, as is the case with reported prevalence of CVD.31 Furthermore, other genetic or inflammatory risk factors could modify the relationships of MetS and diabetes with AVC. It was beyond the scope of the present report to investigate these issues.
In conclusion, results from this adult population–based cohort provide support for a link between the presence of MetS and the presence of AVC. They further underscore the importance of recognizing and treating individual components of MetS, particularly elevated blood pressure and dyslipidemia. Further study is warranted to determine whether screening for aortic valve disease should be recommended in those with MetS or diabetes. Also, given differing findings with regard to the efficacy of either statin therapy or ACE inhibitors in calcific aortic valve disease,32–36 further investigation is needed to define whether those interventions, as well as interventions that directly target insulin resistance in MetS, might retard or reverse AVC.
|
Acknowledgments |
|---|
This research was supported by R01-HL-63963-01A1, contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169, and grant DK02456 from the National Heart, Lung, and Blood Institute.
Disclosures
Dr Wong has received research grants from Pfizer and Bristol-Myers Squibb and is on the speakers’ bureaus of Pfizer, Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, and Sanofi-Aventis. Dr Budoff has received honoraria from and is on the speakers’ bureau of General Electric. Dr O’Brien is on the speakers’ bureau of Takeda Pharmaceutical Company Limited and has served as a consultant for Sanofi-Aventis.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999; 341: 142–147.
2. Otto CM, Pearlman AS. Doppler echocardiography in adults with symptomatic aortic stenosis: diagnostic utility and cost-effectiveness. Arch Intern Med. 1988; 148: 2553–2560.
3. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29: 630–634.[Abstract]
4. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med. 2002; 162: 2345–2347.
5. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997; 95: 2262–2270.
6. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation. 1994; 90: 844–853.
7. Olsson M, Rosenqvist M, Nilsson J. Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol. 1994; 24: 1664–1671.[Abstract]
8. O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996; 16: 523–532.
9. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999; 19: 1218–1222.
10. O’Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002; 106: 2224–2230.
11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415–1428.[CrossRef][Medline] [Order article via Infotrieve]
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735–2752.
13. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International Diabetes Federation; 2005. Available at: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed April 14, 2006.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356–359.
15. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76–79.
16. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001; 21: 2051–2058.
17. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitcomb B, Hachamovitch R, Friedman JD, Hayes S, Berman DS. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol. 2003; 41: 1547–1553.
18. Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997; 78: 472–474.
19. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol. 1987; 59: 998–999.[CrossRef][Medline] [Order article via Infotrieve]
20. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001; 88: 693–695.[CrossRef][Medline] [Order article via Infotrieve]
21. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O’Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156: 871–881.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502.[Abstract]
23. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.
24. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005; 28 (suppl 1): S37–S42.
25. Carr JJ, Nelson JC, Wong ND, Nitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005; 234: 35–43.
26. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832.[Abstract]
27. Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology. 1998; 208: 807–814.
28. Budoff MJ, Mao S, Takasu J, Shavelle DM, Zhao XQ, O’Brien KD. Reproducibility of electron-beam CT measures of aortic valve calcification. Acad Radiol. 2002; 9: 1122–1127.[CrossRef][Medline] [Order article via Infotrieve]
29. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol. 2005; 14: 80–87.[CrossRef][Medline] [Order article via Infotrieve]
30. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999; 8: 254–260.[Medline] [Order article via Infotrieve]
31. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52: 1210–1214.
32. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104: 2205–2209.
33. Shavelle DM, Takasu J, Budoff MJ, Mao S, O’Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359: 1125–1126.[CrossRef][Medline] [Order article via Infotrieve]
34. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110: 1291–1295.
35. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352: 2389–2397.
36. O’Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005; 165: 858–862.
|
Footnotes |
|---|
Clinical Trial Registration Information—URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00005487.
Related Article:
Circulation 2006 113: 2031.
This article has been cited by other articles:
 |
|
 |
|
  C. M. Otto Calcific aortic valve disease: outflow obstruction is the end stage of a systemic disease process Eur. Heart J., August 2, 2009; 30(16): 1940 - 1942. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T.M. Ngo, A. L. Sverdlov, S. R. Willoughby, A. K. Nightingale, Y. Y. Chirkov, J. J. McNeil, and J. D. Horowitz Determinants of Occurrence of Aortic Sclerosis in an Aging Population J. Am. Coll. Cardiol. Img., August 1, 2009; 2(8): 919 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Owens and C. M. Otto Is it Time for a New Paradigm in Calcific Aortic Valve Disease? J. Am. Coll. Cardiol. Img., August 1, 2009; 2(8): 928 - 930. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kamalesh, C. Ng, H. El Masry, G. Eckert, and S. Sawada Does diabetes accelerate progression of calcific aortic stenosis? Eur J Echocardiogr, August 1, 2009; 10(6): 723 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Katz, M. J. Budoff, J. Takasu, D. M. Shavelle, A. Bertoni, R. S. Blumenthal, P. Ouyang, N. D. Wong, and K. D. O'Brien Relationship of Metabolic Syndrome With Incident Aortic Valve Calcium and Aortic Valve Calcium Progression: The Multi-Ethnic Study of Atherosclerosis (MESA) Diabetes, April 1, 2009; 58(4): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Otto Calcific Aortic Stenosis -- Time to Look More Closely at the Valve N. Engl. J. Med., September 25, 2008; 359(13): 1395 - 1398. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Oxidation, Inflammation, and Aortic Valve Calcification: Peroxide Paves an Osteogenic Path J. Am. Coll. Cardiol., September 2, 2008; 52(10): 851 - 854. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Greve and K. Wachtell Review: Does lowering cholesterol have an impact on the progression of aortic stenosis? Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 277 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al. Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Arch Intern Med, June 9, 2008; 168(11): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bosse, P. Mathieu, and P. Pibarot Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ix, R. Katz, B. Kestenbaum, L. F. Fried, H. Kramer, C. Stehman-Breen, and M. G. Shlipak Association of Mild to Moderate Kidney Dysfunction and Coronary Calcification J. Am. Soc. Nephrol., March 1, 2008; 19(3): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Vascular Calcification: A Perspective On An Imminent Disease Epidemic IBMS BoneKEy, February 1, 2008; 5(2): 41 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Al-Aly, J.-S. Shao, C.-F. Lai, E. Huang, J. Cai, A. Behrmann, S.-L. Cheng, and D. A. Towler Aortic Msx2-Wnt Calcification Cascade Is Regulated by TNF-{alpha} Dependent Signals in Diabetic Ldlr / Mice Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2589 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res, October 1, 2007; 76(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ix, G. M. Chertow, M. G. Shlipak, V. M. Brandenburg, M. Ketteler, and M. A. Whooley Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study Circulation, May 15, 2007; 115(19): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Towler Imaging Aortic Matrix Metabolism: Mirabile Visu! Circulation, January 23, 2007; 115(3): 297 - 299. [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||